Table 2.
Primary and secondary endpoints at 180 days follow-up in main groups.
| Methylfolate, P5P, Methylcobalamin (n = 26) % Change from Baseline (95% CI) |
Placebo (n = 25) % Change from Baseline (95% CI) |
% Difference (95% CI) | p-Value | |
|---|---|---|---|---|
| Homocysteine | −30.0% (−39.7%, −20.3%) |
1.8% (−4.8%, 6.8%) |
−31.8% (−46.5%, −15.5%) |
p < 0.01 |
| LDL-C | −7.5% (−10.3%, −4.7%) |
2.6% (−1.6%, 5.6%) |
−10.1% (−15.9%, −3.1%) |
p < 0.01 |
| Total cholesterol | −2.5% (−4.8%, −0.3%) |
2.1% (−0.6%, 4.8%) |
−4.6% (−9.6%, 0.3%) |
p = 0.08 |
| HDL-C | 1.6% (−1.4%, 4.6%) |
−0.5% (−3.0%, 2.0%) |
2.1% (−3.4%, 7.6%) |
p = 0.16 |
| Triglycerides | −3.7% (−7.7%, 0.3%) |
2.8% (−0.3%, 5.9%) |
−6.5% (−13.6%, 0.6%) |
p = 0.11 |
| hsCRP | −5.3% (−13.0%, 2.5%) |
−3.2% (−8.3%, 1.9%) |
−2.1% (−14.9%, 10.8%) |
p = 0.23 |